{"entity":{"id":"opm-101","kind":"drug","name":"OPM-101","aka":[],"tldr":"OPM-101 is an experimental oral small-molecule kinase inhibitor from Oncodesign Precision Medicine, in phase 1 trials for advanced melanoma resistant to anti-PD-1.","summary":"OPM-101 is an oral small-molecule kinase inhibitor (macrocyclic, Nanocyclix platform) from Oncodesign Precision Medicine. A highly selective oral RIPK2 inhibitor that blocks the NOD2/RIPK2 pathway; the company says it is designed to reprogram immune responses in cancer and overcome resistance to immunotherapy. Its furthest stage is phase 1, for advanced melanoma resistant to anti-PD-1. ClinicalTrials.gov registers it in one study linked below. Phase 1 in healthy volunteers completed (SAD and MAD). REVERT phase 1b/2a with pembrolizumab in anti-PD-1-resistant melanoma registered, not yet recruiting (NCT07040436). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Oncodesign Precision Medicine: oncodesign.com","url":"https://www.oncodesign.com/our-pipeline/opm-101/"},{"label":"Oncodesign Precision Medicine: oncodesign.com","url":"https://www.oncodesign.com/our-pipeline/opm-101/"},{"label":"Oncodesign Precision Medicine: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07040436"},{"label":"ClinicalTrials.gov: trials of OPM-101","url":"https://clinicaltrials.gov/search?intr=OPM-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["ripk2"],"drugs":[],"companies":["oncodesign-precision-medicine"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07040436"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"OPM-101","modality":"Oral small-molecule kinase inhibitor (macrocyclic, Nanocyclix platform)","mechanism":"A highly selective oral RIPK2 inhibitor that blocks the NOD2/RIPK2 pathway; the company says it is designed to reprogram immune responses in cancer and overcome resistance to immunotherapy.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/opm-101/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"ripk2","kind":"target","name":"RIPK2","route":"/targets/ripk2/"}],"company":[{"id":"oncodesign-precision-medicine","kind":"company","name":"Oncodesign Precision Medicine","route":"/companies/oncodesign-precision-medicine/"}],"trial":[{"id":"nct07040436","kind":"trial","name":"Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1","route":"/trials/nct07040436/"}]}}